Infection risk with abatacept lower than TNF inhibitors in RA

Patients with rheumatoid arthritis who are treated with abatacept as a first- or second-line biologic treatment have a lower risk for hospitalized infection compared with those treated with TNF inhibitors, according to data published in Arthritis Care & Research. “Infection risk is one of the main side effects that we, rheumatologists, discuss with our RA patients when choosing/starting a biologic disease-modifying antirheumatic drug in clinic,” Seoyoung C. Kim, MD, ScD, MSCE, of Brigham and Women’s Hospital, told Healio Rheumatology. “While all DMARDs including